Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

Autor: MacConell L, Pencek R, Li Y, Maggs D, Porter L

Publikováno v: Diabetes, Metabolic Syndrome and Obesity, Vol 2013, Iss default, Pp 31-41 (2013)

Leigh MacConell, Richard Pencek, Yan Li, David Maggs, Lisa PorterAmylin Pharmaceuticals, LLC, San Diego, CA, USABackground: Type 2 diabetes mellitus is a progressive metabolic disease necessitating therapies with sustained efficacy and safety over ti

Externí odkaz: https://doaj.org/article/463c8734474043869501161a968048ae

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Autor: Nevens, F, Andreone, P, Mazzella, G, Strasser, S, Bowlus, C, Drenth, J, Pockros, P, Regula, J, Beuers, U, Trauner, M, Jones, D, Floreani, A, Hohenester, S, Luketic, V, Shiffman, M, van Erpecum, K, Vargas, V, Vincent, C, Hirschfield, G, Shah, H, Hansen, B, Lindor, K, Marschall, H, Kowdley, K, Hooshmand Rad, R, Marmon, T, Sheeron, S, Pencek, R, Macconell, L, Pruzanski, M, Shapiro, D. Collaborator: Carbone, INVERNIZZI, PIETRO

Publikováno v: New England Journal of Medicine, 375(7), 631-643. Massachussetts Medical Society
New England journal of medicine, 375(7), 631-643. Massachussetts Medical Society
New England Journal of Medicine, 375(7), 631. Massachussetts Medical Society
The New England Journal of Medicine, 375, 631-43
The New England Journal of Medicine, 375, 7, pp. 631-43

none 32 BACKGROUND Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or dea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c1282490c2e4da3e25822cd675fd58e
https://doi.org/10.1056/nejmoa1509840

Quinides of Roasted Coffee Enhance Insulin Action in Conscious Rats

Autor: Shearer, Jane ^{*, 2}, Farah, Adriana, de Paulis, Tomas, Bracy, Deanna P. ^*, Pencek, R. Richard ^*, Graham, Terry E. ^**, Wasserman, David H. ^*

Publikováno v: In The Journal of Nutrition November 2003 133(11):3529-3532

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Autor: Kowdley, KV, Luketic, V, Chapman, R, Hirschfield, GM, Poupon, R, Schramm, C, Vincent, C, Rust, C, Parés, A, Mason, A, Marschall, H-U, Shapiro, D, Adorini, L, Sciacca, C, Beecher-Jones, T, Böhm, O, Pencek, R, Jones, D, Obeticholic Acid Pbc Monotherapy Study Group

Publikováno v: Hepatology (Baltimore, Md.). 67(5)

Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy in an international, randomized, double-blind, placebo-controlled phase 2 study in patients with primary biliary cholangitis who were then followed for up to 6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a869e6d6383739ac0b3b408728287d6
https://pubmed.ncbi.nlm.nih.gov/29222924

Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

Autor: Bowlus, C.L., Pockros, P.J., Kremer, A.E., Parés, A., Forman, L.M., Drenth, J.P.H., Ryder, S., Terracciano, L., Floreani, A., Jin, Y., Lieberman, A., Pencek, R., Iloeje, U., MacConell, L., Bedossa, P.

Publikováno v: In Digestive and Liver Disease February 2019 51 Supplement 1:e19-e19